Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation
Author:
Funder
Ewha Womans University
Publisher
Public Library of Science (PLoS)
Subject
Multidisciplinary
Reference24 articles.
1. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology;NI Lindeman;Archives of pathology & laboratory medicine,2018
2. Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives;G Herbreteau;Journal of thoracic disease,2019
3. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study;JY Douillard;British journal of cancer,2014
4. Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial;AJ Redig;JAMA oncology,2016
5. Application of Plasma Genotyping Technologies in Non-Small Cell Lung Cancer: A Practical Review;AG Sacher;Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer,2017
Cited by 45 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Recent Advancements in the Application of Circulating Tumor DNA as Biomarkers for Early Detection of Cancers;ACS Biomaterials Science & Engineering;2024-07-01
2. Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation;Clinical Orthopaedics & Related Research;2024-06-21
3. Machine learning model for circulating tumor DNA detection in chronic obstructive pulmonary disease patients with lung cancer;Translational Lung Cancer Research;2024-01
4. Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC;Journal of Thoracic Oncology;2023-11
5. Biomarker Testing for Actionable Alterations in NSCLC—Perspectives from US-Based Academic and Community Oncologists: A Podcast;Advances in Therapy;2023-10-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3